Jefferies downgraded Inhibrx (INBX) to Hold from Buy with an unchanged $35 price target. The company has evolved into an oncology story following the sale of the AAT asset to Sanofi (SNY), the analyst tells investors in a research note. Inhibrx’s oncology portfolio is interesting, though the firm is moving to enutral until further updates on the pipeline potentially this year pending closing of the deal and the company’s transition to a new entity, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INBX:
- Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Inhibrx Announces Execution of Merger Agreement
- Inhibrx Announces Merger and Spin-Off Agreements with Aventis
- Inhibrx downgraded to Market Perform from Outperform at LifeSci Capital
- M&A News: Sanofi Expands into Rare Diseases with Inhibrx Deal
